脉冲与连续疗法治疗皮肤癣菌性趾甲甲真菌病的疗效与安全性
本研究通过系统综述与网络荟萃分析比较特比萘芬、伊曲康唑和氟康唑连续与脉冲给药治疗皮肤癣菌性趾甲甲真菌病的疗效与安全性。共纳入30项研究进行系统综述,22项进入网络荟萃分析。结果显示特比萘芬和伊曲康唑的连续与脉冲方案在真菌学治愈率上无显著差异,24周连续特比萘芬疗效最优;各方案不良事件风险无显著差异且与安慰剂相似。
要点
- 特比萘芬和伊曲康唑的连续与脉冲方案真菌学治愈率无显著差异。
- 24周连续特比萘芬在排名概率中疗效最优。
- 各口服抗真菌方案的连续与脉冲给药不良事件风险无显著差异。
核心结论
- 治疗皮肤癣菌性趾甲甲真菌病时,特比萘芬和伊曲康唑的连续与脉冲方案疗效及不良事件发生率相似。
研究设计与样本
- 系统综述与网络荟萃分析,系统综述纳入30项研究,网络荟萃分析纳入22项研究。
- 比较特比萘芬、伊曲康唑和氟康唑治疗皮肤癣菌性趾甲甲真菌病的疗效(真菌学治愈)与不良事件率。
主要发现
- 特比萘芬和伊曲康唑各自连续与脉冲方案的真菌学治愈可能性无显著差异。
- 24周连续特比萘芬的真菌学治愈可能性显著高于12周连续伊曲康唑或9-12个月每周氟康唑,但12周连续特比萘芬无此显著优势。
- 排名概率显示24周连续特比萘芬最有效。
- 特比萘芬、伊曲康唑和氟康唑的任何连续与脉冲方案之间不良事件可能性无显著差异,且药物与安慰剂的不良事件可能性相似。
关键数值与推荐
- 24周连续特比萘芬的真菌学治愈可能性显著高于12周连续伊曲康唑或9-12个月每周氟康唑。
- 12周连续特比萘芬与12周连续伊曲康唑或9-12个月每周氟康唑的真菌学治愈可能性无显著差异。
临床怎么用
- 临床可考虑将脉冲给药作为特比萘芬或伊曲康唑连续给药的替代方案,两者疗效与安全性相似。
- 若追求最高真菌学治愈可能性,24周连续特比萘芬为排名最优方案。
局限性
- 原文未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Onychomycosis is a chronic, fungal infection of the nails. Complete cure remains challenging, but oral antifungal medications have been successful in managing the fungus for a significant proportion of patients. Treatment with these drugs can be continuous or intermittent, albeit the evidence on their relative efficacies remains unclear. OBJECTIVE: To determine the relative effectiveness and safety of pulse versus continuous administration, of three common oral therapies for dermatophyte onychomycosis, by conducting multiple-treatment meta-analysis. METHODS: This systematic review and network meta-analysis compared the efficacy (as per mycological cure) and adverse event rates of three oral antifungal medications in the treatment of dermatophyte toenail onychomycosis, namely terbinafine, itraconazole and fluconazole. A total of 30 studies were included in the systematic review, while 22 were included in the network meta-analysis. RESULTS: The likelihood of mycological cure was not significantly different between continuous and pulse regimens for each of terbinafine and itraconazole. Use of continuous terbinafine for 24 weeks - but not 12 weeks - was significantly more likely to result in mycological cure than continuous itraconazole for 12 weeks or weekly fluconazole for 9-12 months. Rank probabilities demonstrated that 24-week continuous treatment of terbinafine was the most effective. There were no significant differences in the likelihood of adverse events between any continuous and pulse regimens of terbinafine, itraconazole and fluconazole. Drug treatments were similar to placebo in terms of their likelihood of producing adverse events. CONCLUSION: More knowledge about the fungal life cycle and drugs' pharmacokinetics in nail and plasma could further explain the relative efficacy and safety of the pulse and continuous treatment regimens. Our results indicate that in the treatment of dermatophyte toenail onychomycosis, the continuous and pulse regimens for terbinafine and itraconazole have similar efficacies and rates of adverse events.
引用
- Gupta AK, Stec N, Bamimore MA, et al. The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2019. PMID: 31746067. doi:10.1111/jdv.16101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。